Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
Jan 08, 2019 - We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Dec 21, 2018 - FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
Dec 19, 2018 - A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Dec 18, 2018 - A number of companies suffered setbacks this year.
Dec 17, 2018 - Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
Dec 12, 2018 - Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
Dec 10, 2018 - Here are five stocks that are attractive and most likely to be takeout targets in 2019.
Dec 04, 2018 - Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.